Suvi T. M. Orr

机构：Tracon Pharmaceuticals (United States)

发表论文 27 篇 · 总被引 1070 次 · h-index 16

代表论文

• Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks (2012 · Journal of Medicinal Chemistry · 被引 220)
• Discovery of 1-{(3 R ,4 R )-3-[({5-Chloro-2-[(1-methyl-1 H -pyrazol-4-yl)amino]-7 H -pyrrolo[2,3- d ]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants (2016 · Journal of Medicinal Chemistry · 被引 94)
• Discovery of N -((3 R ,4 R )-4-Fluoro-1-(6-((3-methoxy-1-methyl-1 H -pyrazol-4-yl)amino)-9-methyl-9 H -purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR (2017 · Journal of Medicinal Chemistry · 被引 91)
• Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2) (2015 · Journal of Medicinal Chemistry · 被引 85)
• Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate (2014 · ACS Medicinal Chemistry Letters · 被引 71)
• CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety (2025 · Cancer Cell · 被引 61)